Report

The Alzheimer's Disease Diagnostics and Therapeutics Market size is estimated at USD 7.65 billion in 2024, and is expected to reach USD 9.78 billion by 2029, growing at a CAGR of 5.06% during the forecast period (2024-2029).

The emergence of the COVID-19 pandemic impacted the Alzheimer's disease diagnostics and therapeutics market, as diagnostic and therapeutic procedures worldwide were Alzheimer's due to the decline in visits to hospitals and diagnostic centers because of government regularizations globally in early 2020. For instance, an article published in Brain Sci. in February 2021 stated that patients with dementia were at increased risk of severe disease and death when infected with COVID-19. Thus, as a measure of prevention, there is a decrease in the treatment and diagnostic visits to hospitals and other healthcare facilities. However, as better access to affectedAlzheimer'sr's diagnostic and therapeutic services is currently compared to the initial pandemic times, the market is expected to regain its growth pace over the studied period.

The major factors driving the growth of the Alzheimer's disease diagnostics and therapeutics market are the increasing use of biomarkers in Alzheimer's diagnosis and drug development and the rising prevalence of Alzheimer's worldwide. For instance, in September 2022, a report by the WHO stated that about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. WHO also said that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia.

Also, with the growing prevalence of Alzheimer's around the world, government and non-government entities are investing heavily in developing diagnostics and therapeutics for the disease, which may augment the market's growth. For instance, in June 2021, the ADDF Diagnostics Accelerator launched four new research investments to develop digital biomarkers for Alzheimer's diagnosis. Investments like these are further expected to propel the market growth.

Additionally, with the advancement in diagnostic technologies and ongoing research activities in the area, the companies are enhancing their product offering and launching new products coupled with other business expansion initiatives like mergers and acquisitions, strategic collaboration, and new investments into other companies are also expected to complement the growth of the Alzheimer's disease diagnostics and therapeutics market over the forecast period. For instance, in November 2021, Brigham and Women's Hospital in Boston, United States, started a clinical trial to test the safety and efficacy of a new nasal vaccine for Alzheimer's disease. Thus, such therapeutics development leads to better drugs for Alzheimer's treatments, thereby driving the growth of the studied market.

Thus, due to the use of biomarkers, increasing research and development, and advanced diagnostic technologies, the studied market is expected to witness healthy growth over the forecast period. However, high failure rates of clinical studies related to diagnosis and treatment and challenges in early diagnostics of Alzheimer's may impede the market growth over the forecast period.

Alzheimer's Disease Diagnostics & Therapeutics Market Trends

Cholinesterase Inhibitors is Expected to Witness a Significant Growth Over the Forecast Period.

Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are a class of therapeutics that stop the normal breakdown of acetylcholine, a neurotransmitter. The cholinesterase inhibitors shut off the action of the enzyme cholinesterase, which is responsible for breaking down acetylcholine neurotransmitters in the body. As cholinesterase inhibitors are found to slightly delay the loss of brain function in people suffering from mild to moderate focus Alzheimers disease, they are widely prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Currently, the major cholinesterase inhibitor drugs available and Alzheimer's use in the market are donepezil, galantamine, rivastigmine, and memantine.

Currently, in the market, cholinesterase inhibitors are the Alzheimer's drugs available for Alzheimer's because the enzyme cholinesterase is a significant therapeutic primary for Alzheimer's. Hence, the segment is expected to grow over the forecast period as several pharmaceutical companies Alzheimer's developing Alzheimer's therapeutics based on cholinesterase inhibitors. For instance, in October 2021, Corium, Inc., reported the USFDA has set a PDUFA target actionCorium'sium's new drug application for once-weekly ADLARITY (donepezil transdermal systcommonly it's a patch formulation of donepezil. This patch treats dementia due to mild, moderate, or severe Alzheimer's disease.

Also, an article published by AGS journal in December 2021 stated that older adults with Alzheimer's disease respond better when treated with cholinesterase inhibitors. Thus, the rising geriatric population with Alzheimer's disease is leading to increasing demand for cholinesterase inhibitors, thereby contributing to the growth of this segment.

Thus, due to the practical results of cholinesterase inhibitors in treating Alzheimer's disease, new product launches and the increasing geriatric population is expected to witness significant growth over the forecast period.

North America is Expected to Witness a Significant Growth Over the Forecast Period.

North America is expected to witness significant growth over the forecast period owing to the high burden of Alzheimer's disease and the increasing aging population, huge investment in research and development activities, and the launch of new products in the region. For instance, in June 2021, in an interview, the Chief Science Officer of the Alzheimer's Society of Canada stated that in the upcoming 10 years, it is anticipated that more than one million people in Canada will be living with dementia. This indicates that the increasing prevalence of Alzheimer's in the North American region is expected to increase the demand for diagnostic and therapeutic products for Alzheimer's, which may drive market growth over the forecast period.

Also, the growing aging population in the region is expected to increase the burden of Alzheimer's disease, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer's as it is an age-associated disease. For instance, in March 2022, the Alzheimer's Association Report stated that approximately 6.2 million people of age 65 years and more are living with Alzheimer's-related dementia in the United States, and it is projected that this number will increase to 13.8 million people by 2060.

With the increasing number of research studies related to the diagnosis and management of Alzheimer's disease and high investment in the country over Alzheimer's by the government and private entities, the market is expected to grow in the United States over the forecast period. For instance, in October 2021, Salk Institute initiated a phase 1 clinical trial of the investigational Alzheimer's drug CMS121 to evaluate its safety in humans. Thus, such pipeline drugs are leading to the development of better therapeutics for Alzheimer's disease, thereby driving the growth of the studied market in the region.

Therefore, due to the high burden of Alzheimer's disease and huge investment in research and development activities, coupled with the launch of new products, the Alzheimer's disease diagnostics, and therapeutics market is expected to grow over the forecast period in the region.

Alzheimer's Disease Diagnostics & Therapeutics Industry Overview

The Alzheimer's disease diagnostics and therapeutics market is moderately competitive and consists of several significant players; some of the companies are F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc., Eisai Co. Ltd, Biogen Inc., Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc., Siemens Healthineers, Zydus Cadila, Merz Pharma, Teva Pharmaceutical Industries Ltd., and Adamas Pharmaceuticals Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support